11:10 AM EDT, 05/11/2026 (MT Newswires) -- The UK's Medicines and Healthcare products Regulatory Agency said Monday it is updating the product information for medicines containing finasteride and dutasteride following a further review of evidence on their side effects.

For the 1-milligram androgenetic alopecia treatment finasteride, the update clarifies that sexual dysfunction may contribute to mood disorders, and that such side effects have been reported both with and without mood changes.

The regulator also issued a precautionary warning for the 0.5-milligram benign prostatic hyperplasia treatment dutasteride, noting the mood-related side effects of finasteride, which belongs to the same drug class.